Home / Stocks / BIO

Bio-Rad Laboratories (BIO, Lab tools & research services) Stock Valuation & Fair Value

Mixed on our tests

Bio-Rad Laboratories (BIO, Lab tools & research services) trades at a current P/E of 38.1, about 19% above its historical normal valuation, with a forward growth estimate of 7.8% and a PEG of 4.90. Analysts' one-year estimates have been hit 18% of the time. Priced at its historical normal P/E of 32.1 on the same blended earnings, the 2026-10-30 close of $372.18 corresponds to about $314 a share. This is a valuation reference, not a price target.

How to read these numbers: the PEG ratio and current P/E versus normal P/E.

DATA AS OF 2026-10-31
Current P/E
38.1
Normal P/E
32.1
PEG
4.90
Fwd growth
7.8%
Div yield
0.0%
RSI (14)
—

Valuation flags

Verdict history

tickerseer's rating has been poor on forward returns since 2026-07-31.

Current P/E and rating by weekCurrent P/E moved from 34.9 to 40.0 between 2026-07-31 and 2026-09-11, against a normal P/E of 32.1, with 0 rating changes over 7 recorded weeks.2026-07-31: P/E 34.9, Poor on forward returns, recalculated for the week of 2026-07-312026-07-31: P/E 34.8, Poor on forward returns, recorded live 2026-08-032026-08-07: P/E 34.8, Poor on forward returns, recalculated for the week of 2026-08-072026-08-07: P/E 34.9, Poor on forward returns, recorded live 2026-08-102026-08-14: P/E 34.9, Poor on forward returns, recalculated for the week of 2026-08-142026-08-14: P/E 34.9, Poor on forward returns, recorded live 2026-08-172026-08-21: P/E 34.9, Poor on forward returns, recalculated for the week of 2026-08-212026-08-21: P/E 39.3, Poor on forward returns, recorded live 2026-08-242026-08-27: P/E 39.3, Poor on forward returns, recalculated for the week of 2026-08-272026-08-28: P/E 39.3, Poor on forward returns, recalculated for the week of 2026-08-282026-08-28: P/E 39.3, Poor on forward returns, recalculated for the week of 2026-08-302026-08-28: P/E 40.1, Poor on forward returns, recorded live 2026-08-312026-09-04: P/E 40.1, Poor on forward returns, recalculated for the week of 2026-09-052026-09-04: P/E 40.0, Poor on forward returns, recorded live 2026-09-072026-09-11: P/E 40.0, Poor on forward returns, recalculated for the week of 2026-09-1232.535.037.540.0Jul 31Aug 10Aug 21Sep 1Sep 11Normal P/E 32.1
Poor on forward returns

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-07-31P/E 34.9+9%Poor on forward returns (recalculated)
2026-08-03P/E 34.8+8%Poor on forward returns
2026-08-31P/E 40.1+25%Poor on forward returns
2026-09-12P/E 40.0+25%Poor on forward returns (recalculated) ← now
Show all 15 readings
WeekCurrent P/EPremium to normal P/ERating
2026-07-31P/E 34.9+9%Poor on forward returns (recalculated)
2026-08-03P/E 34.8+8%Poor on forward returns
2026-08-07P/E 34.8+8%Poor on forward returns (recalculated)
2026-08-10P/E 34.9+9%Poor on forward returns
2026-08-14P/E 34.9+9%Poor on forward returns (recalculated)
2026-08-17P/E 34.9+9%Poor on forward returns
2026-08-21P/E 34.9+9%Poor on forward returns (recalculated)
2026-08-24P/E 39.3+22%Poor on forward returns
2026-08-27P/E 39.3+22%Poor on forward returns (recalculated)
2026-08-28P/E 39.3+22%Poor on forward returns (recalculated)
2026-08-30P/E 39.3+22%Poor on forward returns (recalculated)
2026-08-31P/E 40.1+25%Poor on forward returns
2026-09-05P/E 40.1+25%Poor on forward returns (recalculated)
2026-09-07P/E 40.0+25%Poor on forward returns
2026-09-12P/E 40.0+25%Poor on forward returns (recalculated) ← now

Frequently asked questions

Is Bio-Rad Laboratories stock overvalued?

At a current P/E of 38.1 versus its historical normal P/E of 32.1, Bio-Rad Laboratories trades about 19% above its typical valuation, with a PEG of 4.90 on 7.8% forward growth. tickerseer currently rates it mixed on our tests.

What is Bio-Rad Laboratories's fair value and PEG?

Bio-Rad Laboratories trades at a current P/E of 38.1 against a historical normal P/E of 32.1, a PEG of 4.90, and a forward growth estimate of 7.8%. Priced at its historical normal P/E of 32.1 on the same blended earnings, the 2026-10-30 close of $372.18 corresponds to about $314 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Bio-Rad Laboratories changed?

tickerseer's rating has been poor on forward returns since 2026-07-31.

Industry: Lab tools & research services. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track BIO free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.